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Xeroderma pigmentosum (XP, OMIM 278700–278780) is a
rare cutaneous autosomal recessive disorder associated with
severe morbidity and poor prognosis.
In June 2010 issue of the Journal of Investigative Dermatol-
ogy, Souﬁr et al. (2010) elegantly demonstrated the founder
mutation c.1643_1644delTG (p.Val548Ala fsX25) in the XP-
C gene as a responsible gene for a large proportion (87%) of
cases with XP-C from North Africa. Subsequently, Tamura
et al. (2010) have suggested that the presence of this founder
mutation provides an opportunity for early diagnosis of XP
and genetic counseling. Similarly, back in 2009 Ben Rekaya
et al. (2009) had also reported high frequency of the
c.1643_1644delTG mutation in Tunisian families and
suggested direct screening of this mutation for diagnosis ofAbbreviations: XP-C, Xeroderma pigmentosum C; UV, ultra violet
light.
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way for routine molecular assessment of XP cases.
In this report, we intend to reiterate the importance of the
work of Souﬁr et al. (2010), and provide further validation of
his ﬁndings by reﬂecting our own experience with respect to
application of the c.1643_1644delTG mutation in genetic test-
ing for XP-C. Recently, in the Dermatology Clinic of King
Fahad Hospital of the University (FHU, Dammam, Saudi
Arabia) we encountered three consanguineous families (two
were of Saudi Arabian origin, and one of North Sudan origin
as seen in Fig. 1) with seven severely affected XP patients. Five
of the patients had already developed cancers. In the Sudanese
family, heterozygosity for the c.1643_1644delTG mutation in
the parents and homozygosity in two siblings diagnosed with
XP-C were detected by direct nucleotide sequencing. This
frame-shift mutation could neither be detected in a healthy sis-
ter of the two patients, nor in any member of the two other
Saudi families including 5 XP patients. Interestingly,
Mahindra et al. (2008) had also described XP-C in two brother
patients from another Sudanese family from North Sudan.
Both patients were homozygous for the founder XP-C dis-
ease-causing mutation c.1643_1644delTG, whereby the clinical
and pathological ﬁndings were strikingly similar to those seen
in one patient of our Sudanese family. However, to the best of
our knowledge, there is no blood relationship between these
two Sudanese families. The absence of c.1643_1644delTG in
the two affected families of Saudi Arabian origin strengthens
the assumption of a North African origin of this mutation.vier B.V. All rights reserved.
Figure 1 Pedigree of a Sudanese family affected with XP-C.
Mutation c.1643_1644delTG was detected in the heterozygous
state in the obligatory parents, in the homozygous state in patient
(XPF1 II:3) and in his patient sister (XPF1 II:4), but not in a
healthy sister of the two patients (XPF1 II:6).
86 El-Harith A. El-Harith et al.In conclusion, results ensuing form genetic testing are
sensitive and speciﬁc and enable early detection of the molec-
ular defect, thereby simplifying disease diagnosis in neonates
and infants. Furthermore, early diagnosis (or prediction)
may improve prognosis of the disease, and enhance effective
genetic counseling especially in communities with high mar-
riage consanguinity, like Sudan and Saudi Arabia.Acknowledgements
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